MicroRNA 222 was identified as a key molecular in temozolomide-resistant glioma patients, and knockdown of microRNA 222 sensitized glioma cells to temozolomide by regulating the expression of apoptosis-independent p53. Here, TP53 is linked to central nervous system cancer.